A Phase 3 study involving tofacitinib for rheumatoid arthritis reached primary completion on 2026-01-15. This trial, which enrolled 459 participants, compared TLL-018 to tofacitinib in subjects with an inadequate response or intolerance to biologic DMARDs.
Background
Tofacitinib (Xeljanz, Xeljanz XR) is an intervention being studied in rheumatoid arthritis. The current Phase 3 study investigated its role in subjects who had an inadequate response or intolerance to Biologic DMARDs.
Trial design
The Phase 3 study (NCT06020144) enrolled 459 participants with rheumatoid arthritis. It is a randomized, double-blind, double-dummy, positive-controlled study designed to assess the safety and efficacy of TLL-018 in comparison to tofacitinib. Participants included those with active rheumatoid arthritis who had an inadequate response or intolerance to Biologic DMARDs.
What this means
The primary completion of this Phase 3 study signifies that the main data collection period for the trial has concluded. While this marks a significant milestone in the study's progression, detailed efficacy and safety results comparing TLL-018 to tofacitinib in rheumatoid arthritis subjects are not yet available. Clinicians and researchers will need to await the full publication of the trial's outcomes to understand the comparative safety and efficacy profiles of these interventions in the studied population.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06020144, titled "A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs", was posted on 2026-01-15 on clinicaltrials.gov.